Correlation of somatic mutations and clinical outcome in melanoma patients treated with carboplatin, paclitaxel, and sorafenib

PURPOSE: Sorafenib is an inhibitor of VEGFR, PDGFR, and RAF kinases, amongst others. We assessed the association of somatic mutations with clinicopathologic features and clinical outcomes in patients with metastatic melanoma treated on E2603, comparing treatment with carboplatin, paclitaxel +/− sora...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Wilson, Melissa A., Zhao, Fengmin, Letrero, Richard, D’Andrea, Kurt, Rimm, David L., Kirkwood, John M., Kluger, Harriet M., Lee, Sandra J., Schuchter, Lynn M., Flaherty, Keith T., Nathanson, Katherine L.
Format: Artigo
Sprog:Inglês
Udgivet: 2014
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4058354/
https://ncbi.nlm.nih.gov/pubmed/24714776
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-0093
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker